Physician Nurses Other: Other Value

a. Follow up cystoscopy and cytology in 3 months
b. Intravesical BCG weekly for 6 weeks
c. Intravesical mitomycin C weekly for 6 weeks
d. Radical cystectomy

a. Median duration of response of 16 months
b. 40% of patients with response lasting ≥12 months
c. Complete response rate <20%
d. All of the above are true

a. In the ITT population
b. Only in patients with PD-L1 ≥1%
c. Only in patients who were randomized to nivolumab within 30 days of surgery
d. Only in patients who had not received prior neoadjuvant cisplatin

a. The confirmed overall response rates with avelumab were equivalent in the overall population and the population with PD-L1 ≥1%
b. Nearly 10% of patients with PD-L1 ≥1% exhibited a complete response
c. Progressive disease was observed in >50% of the patients with PD-L1 ≥1%
d. The disease control rate in the avelumab groups was about the same as in the control group, regardless of PD-L1 status

a. FGFR1
b. FGFR2
c. FGFR3
d. All of the above

a. ERCC2
b. ATM
c. RB1
d. All of the above

a. An objective response rate of 40%
b. Median progression-free survival of 2 months
c. Median overall survival of 6 months
d. All of the above

a. Central serous retinopathy
b. Hyperphosphatemia
c. Hypophosphatemia
d. Hand-foot syndrome

a. Overall response rate
b. Median progression-free survival
c. Median overall survival
d. All of the above

Strongly Agree
Agree
Disagree
Strongly disagree

Yes No

Do nothing because the content was not convincing
Change my practice
Seek additional information on this topic
Do nothing as current practice reflects activity recommendations
Do nothing as lack of organizational support prevents my adoption of presented guidelines and recommendations
Do nothing as lack of financial support prevents my adoption of presented guidelines and recommendations
Other: Other Value

Diagnosis
Patient Safety
Documentation (appropriate)
Treatment approach
Patient Education
Medication

1.5